US · Healthcare · Biotechnology
EPS came in at 0.05 against a street estimate of 0.01 — a beat of 400.0%.
Analysts rate Fennec Pharmaceuticals Inc a strong buy (6 buy, 0 hold, 0 sell out of 6) with an average price target of $17.67.
| Fund | Stake |
|---|---|
| Rosalind Advisors, Inc. | 9.09% |
| AIGH Capital Management, LLC | 7.09% |
| Solas Capital Management LLC | 5.39% |
| BlackRock Inc | 4.92% |
| Awm Investment Company Inc | 3.31% |
| Vanguard Capital Management, LLC | 2.39% |
| Prospect Capital Advisors, LLC | 1.42% |
| State Street Corp | 1.21% |
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Fennec Pharmaceuticals Inc — free to start.
Open in the appGoogle PlayApp StoreData updated 2026-10-19.